{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:57:50Z","timestamp":1790647070096,"version":"4.1.0"},"reference-count":86,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The high expression of CD7 targets in T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoma has attracted considerable attention from researchers. However, because CD7 chimeric antigen receptor (CAR) T-cells undergo fratricide, CD7 CAR T-cells develop an exhaustion phenotype that impairs the effect of CAR T-cells. There have been significant breakthroughs in CD7-targeted CAR T-cell therapy in the past few years. The advent of gene editing, protein blockers, and other approaches has effectively overcome the adverse effects of conventional methods of CD7 CAR T-cells. This review, in conjunction with recent advances in the 64<jats:sup>th<\/jats:sup> annual meeting of the American Society of Hematology (ASH), provides a summary of the meaningful achievements in CD7 CAR T-cell generations and clinical trials over the last few years.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1170968","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T05:06:55Z","timestamp":1683263215000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances"],"prefix":"10.3389","volume":"14","author":[{"given":"Jile","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1177\/1535370215584936","article-title":"From humble beginnings to success in the clinic: chimeric antigen receptor-modified T-cells and implications for immunotherapy","volume":"240","author":"Firor","year":"2015","journal-title":"Exp Biol Med (Maywood NJ)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/j.molonc.2015.10.012","article-title":"CAR T-cell immunotherapy: the path from the by-road to the freeway","volume":"9","author":"Whilding","year":"2015","journal-title":"Mol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.967754","article-title":"Chimeric antigen receptor T-cell therapy for T-ALL and AML","volume":"12","author":"Wei","year":"2022","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s11864-023-01049-4","article-title":"Small-molecule compounds boost CAR-T cell therapy in hematological malignancies","volume":"24","author":"Cao","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-0146-4_4","article-title":"Production of lentivirus for the establishment of CAR-T cells","volume":"2086","author":"Lana","year":"2020","journal-title":"Methods Mol Biol (Clifton NJ)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1039\/D1LC00219H","article-title":"mRNA-based CAR T-cells manufactured by miniaturized two-step electroporation produce selective cytotoxicity toward target cancer cells","volume":"21","author":"Jayasooriya","year":"2021","journal-title":"Lab Chip"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T Cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet (London England)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in b cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Trans Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in b-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12910","article-title":"Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed\/refractory multiple myeloma","volume":"92","author":"Feng","year":"2020","journal-title":"Scandinavian J Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int J Biol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1819978","article-title":"Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors","volume":"21","author":"Date","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14375","article-title":"CAR-T cell therapy for lung cancer: potential and perspective","volume":"13","author":"Chen","year":"2022","journal-title":"Thorac Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.2.603","article-title":"Isolation and characterization of the genomic human CD7 gene: structural similarity with the murine thy-1 gene","volume":"88","author":"Schanberg","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.76.11.5829","article-title":"Human lymphocyte antigens: production of a monoclonal antibody that defines functional thymus-derived lymphocyte subsets","volume":"76","author":"Haynes","year":"1979","journal-title":"Proc Natl Acad Sci USA"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.152.2.517","article-title":"Expression and function of CD7 molecule on human natural killer cells","volume":"152","author":"Rabinowich","year":"1994","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14020","article-title":"The role of antiviral prophylaxis for the prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review","volume":"17","author":"AlDabbagh","year":"2017","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surgeons"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-Human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(03)00180-2","article-title":"Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia","volume":"28","author":"Chang","year":"2004","journal-title":"Leukemia Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03139.x","article-title":"Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia","volume":"115","author":"Ogata","year":"2001","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.06.001","article-title":"CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype","volume":"31","author":"Chang","year":"2007","journal-title":"Leukemia Res"},{"key":"B25","article-title":"Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin a-chain immunotoxin DA7","volume":"52","author":"Jansen","year":"1992","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3109\/10428199709051778","article-title":"Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin a chain immunotoxin","volume":"26","author":"Frankel","year":"1997","journal-title":"Leukemia Lymphoma"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.150.5.2081","article-title":"CD7- T cells represent a subset of normal human blood lymphocytes","volume":"150","author":"Reinhold","year":"1993","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.07.006","article-title":"Aggressive characteristics of myeloblasts expressing CD7 in myelodysplastic syndromes","volume":"33","author":"Satoh","year":"2009","journal-title":"Leukemia Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.12.5749","article-title":"Immunologic characterization of CD7-deficient mice","volume":"160","author":"Lee","year":"1998","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/9.12.1875","article-title":"Targeted gene disruption of murine CD7","volume":"9","author":"Bonilla","year":"1997","journal-title":"Int Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.149819","article-title":"CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy","volume":"6","author":"Kim","year":"2021","journal-title":"JCI Insight"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Sci (New York NY)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","article-title":"Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer","volume":"21","author":"Wang","year":"2022","journal-title":"Mol Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2577","article-title":"Evolution and classification of the CRISPR-cas systems","volume":"9","author":"Makarova","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \"off-the-shelf\" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.10.001","article-title":"CD7 CAR T cells for the therapy of acute myeloid leukemia","volume":"27","author":"Gomes-Silva","year":"2019","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"B37","first-page":"64","article-title":"A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia","volume":"9","author":"You","year":"2019","journal-title":"Am J Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014498","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3389\/fimmu.2021.765097","article-title":"CAR-T cell therapy in T-cell malignancies: is success a low-hanging fruit","volume":"12","author":"Safarzadeh Kozani","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2","article-title":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant b-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Trans Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for Relapsed\/Refractory b-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158682","article-title":"Universal anti-CD7 CAR-T cells targeting T-ALL and functional analysis of CD7 antigen on T\/CAR-T cells","volume":"140","author":"Xie","year":"2022","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41392-022-00898-z","article-title":"T Cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape","volume":"7","author":"Dai","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B46","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy","volume":"12","author":"Han","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1271","article-title":"Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A human orthogonal IL-2 and IL-2R\u03b2 system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci Trans Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165733","article-title":"A novel universal CD7-targeted CAR-T cell therapy for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma","volume":"140","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","article-title":"Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing","volume":"53","author":"Leibowitz","year":"2021","journal-title":"Nat Genet"},{"key":"B52","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.1038\/s41586-018-0380-z","article-title":"Large Deletions induced by Cas9 cleavage","volume":"560","author":"Adikusuma","year":"2018","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Sci (New York NY)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1038\/s41467-020-15887-5","article-title":"Cytosine base editors with minimized unguided DNA and RNA off-target events and high on-target activity","volume":"11","author":"Yu","year":"2020","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-00943-2","article-title":"Adenine base editor engineering reduces editing of bystander cytosines","volume":"39","author":"Jeong","year":"2021","journal-title":"Nat Biotechnol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01533-6","article-title":"Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity","author":"Neugebauer","year":"2022","journal-title":"Nat Biotechnol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015825","article-title":"Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL","volume":"140","author":"Diorio","year":"2022","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168719","article-title":"Single and combinational multiplex base-edited 'Universal' CAR T cells in a humanised model of primary CD7+CD33+ AML","volume":"140","author":"Kloos","year":"2022","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169114","article-title":"Tvt CAR7: phase 1 clinical trial of base-edited \"Universal\u201d CAR7 T cells for paediatric Relapsed\/Refractory T-ALL","volume":"140","author":"Chiesa","year":"2022","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017012823","article-title":"A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells","volume":"2","author":"Kamiya","year":"2018","journal-title":"Blood Adv"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162222","article-title":"Development of anti-CD3 chimeric antigen receptor (CAR)-T cells for allogeneic cell therapy of peripheral T-cell lymphoma (PTCL)","volume":"140","author":"Qian","year":"2022","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165822","article-title":"Development of an off-the-Shelf chimeric antigen receptor (CAR)-T cell therapy for T-cell acute lymphoblastic leukemia (T-ALL) without gene editing","volume":"140","author":"Wong","year":"2022","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4097","article-title":"Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic Leukemia\/Lymphoma","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165819","article-title":"Efficacy and safety of donor-derived CD7 CAR T cells for r\/r T-cell acute lymphoblastic Leukemia\/Lymphoma: interim analysis from a phase 2 trial","volume":"140","author":"Tan","year":"2022","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","first-page":"abstr 7028","DOI":"10.1200\/JCO.2022.40.16_suppl.7028","article-title":"Phase I study of donor-derived CD5 CAR T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia","author":"Pan","year":"2022","journal-title":"Am Soc Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-020-10092-9","article-title":"Treatment of aggressive T cell lymphoblastic lymphoma\/leukemia using anti-CD5 CAR T cells","volume":"17","author":"Feng","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0009","article-title":"The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy","volume":"3","author":"Waldmann","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015020","article-title":"Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies","volume":"140","author":"Freiwan","year":"2022","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20368","article-title":"A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China","volume":"74","author":"Zheng","year":"2008","journal-title":"Cytometry Part B Clin Cytometry"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401067","article-title":"Prognostic relevance of the expression of tdt and CD7 in 335 cases of acute myeloid leukemia","volume":"12","author":"Venditti","year":"1998","journal-title":"Leukemia"},{"key":"B75","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158878","article-title":"Analysis of 53 patients with relapsed or refractory (R\/R) T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) treated with CD7-targeted CAR-T cell therapy","volume":"140","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"107731","DOI":"10.1016\/j.intimp.2021.107731","article-title":"Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia","volume":"96","author":"Xie","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.02.013","article-title":"Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody","volume":"24","author":"Ye","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170819","article-title":"Allogeneic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T cell malignancies","volume":"140","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1182\/blood-2021-146425","article-title":"First-in-Human clinical study of a novel CD7-targeted chimeric antigen receptor (CAR)-T cell therapy for Refractory\/Relapsed mixed phenotype acute leukemia (MPAL)","volume":"138","author":"Zhang","year":"2021","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166611","article-title":"Preclinical development of non-edited CD7 CAR-modified invariant NKT cell therapy for T-cell malignancies and acute myeloid leukemia","volume":"140","author":"Zhou","year":"2022","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-022-2173-9","article-title":"Loop CD20\/CD19 CAR-T cells eradicate b-cell malignancies efficiently","volume":"66","author":"Chen","year":"2023","journal-title":"Sci China Life Sci"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3259","article-title":"Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large b cell lymphoma","volume":"9","author":"Sang","year":"2020","journal-title":"Cancer Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood.2021013648","article-title":"Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia","volume":"140","author":"Maciocia","year":"2022","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1170968\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T05:07:01Z","timestamp":1683263221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1170968\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":86,"alternative-id":["10.3389\/fimmu.2023.1170968"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1170968","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"article-number":"1170968"}}